Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Ptc Therapeutics (PTCT) EBITDA (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of EBITDA data on record, last reported at -$792.0 million in Q4 2025.

  • For Q4 2025, EBITDA fell 387.71% year-over-year to -$792.0 million; the TTM value through Dec 2025 reached $84.1 million, up 127.8%, while the annual FY2025 figure was $146.3 million, 148.35% up from the prior year.
  • EBITDA reached -$792.0 million in Q4 2025 per PTCT's latest filing, down from -$23.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $970.2 million in Q1 2025 and bottomed at -$792.0 million in Q4 2025.
  • Average EBITDA over 5 years is -$74.0 million, with a median of -$89.4 million recorded in 2022.
  • Peak YoY movement for EBITDA: plummeted 2890.19% in 2024, then skyrocketed 2234.57% in 2025.
  • A 5-year view of EBITDA shows it stood at -$84.7 million in 2021, then tumbled by 136.45% to -$200.3 million in 2022, then skyrocketed by 102.91% to $5.8 million in 2023, then tumbled by 2890.19% to -$162.4 million in 2024, then tumbled by 387.71% to -$792.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$792.0 million in Q4 2025, -$23.1 million in Q3 2025, and -$71.1 million in Q2 2025.